Real-world disease, patient characteristics and treatment patterns in patients with Non-Small Cell Lung Cancer and extensive stage Small cell lung cancer in Belgium [AIBED]

First published: 30/06/2025

Last updated: 30/06/2025





Administrative details

EU PAS number	
EUPAS100000396	
Study ID	
100000396	
DARWIN EU® study	
No	
Study countries	
-	
Belgium	

Study description

This multicenter study describes demographics, biomarker testing, and treatment patterns in Belgian patients with lung cancer by leveraging natural language processing and the OMOP common data model.

Study status

Finalised

Research institutions and networks

Institutions

AZ Maria Middelares General Hospital Belgium First published: 01/02/2024 Last updated: 01/02/2024 Institution Hospital/Clinic/Other health care facility

AstraZeneca

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Universitair Ziekenhuis Antwerpen (UZA)

Belgium
First published: 11/06/2025
Last updated: 16/06/2025
Institution Hospital/Clinic/Other health care facility
Laboratory/Research/Testing facility ENCePP partner

Universitair Ziekenhuis Brussel Algemeen Ziekenhuis Groeninge Universitair Ziekenhuis Leuven LynxCare Clinical Informatics

Contact details

Study institution contact

Katoo Muylle katoo.muylle@astrazeneca.com

Study contact

katoo.muylle@astrazeneca.com

Primary lead investigator

Katoo Muylle 0000-0003-1117-6709

Primary lead investigator

ORCID number:

0000-0003-1117-6709

Study timelines

Date when funding contract was signed

Actual: 02/12/2019

Study start date

Actual: 01/10/2023

Date of final study report

Planned: 31/05/2022 Actual: 28/06/2024

Sources of funding

Pharmaceutical company and other private sector

More details on funding

AstraZeneca BeLux

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Study type:

Non-interventional study

Scope of the study:

Disease epidemiology

Drug utilisation

Data collection methods:

Secondary use of data

Study design:

Multicenter study (n = 5) analyzing routinely collected data from pseudonymized electronic health records (EHRs) using natural language processing (NLP) for unstructured sources. The algorithm mapped variables to a standard terminology, generating OMOP CDM databases, validated per hospital.

Main study objective:

This study describes the following in Belgian patients with lung cancer for specific subpopulations of interest (Patients with stage IB-IIIB NSCLC, stage III unresected NSCLC, Stage IV NSCLC, or ES-SCLC):

- Demographics
- Biomarker testing with focus on EGFR and PD-L1
- Treatment patterns with focus on durvalumab and osimertinib

Study Design

Non-interventional study design

Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

OSIMERTINIB

DURVALUMAB

Medical condition to be studied

Non-small cell lung cancer

Small cell lung cancer

Population studied

Short description of the study population

Non-small cell lung cancer and small cell lung cancer diagnosed between 1 January 2019 and 31 December 2021.

Estimated number of subjects

2000

Study design details

Setting

Belgium, diagnosis between 2019 and 2021

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s)

LynxCare

Use of a Common Data Model (CDM)

CDM mapping

Yes

CDM Mappings

CDM name

OMOP

CDM website

https://www.ohdsi.org/Data-standardization/

CDM version

5.4

Data quality specifications

Ch	ook	60 ID	for	-	
Ln	eck	con	TOR	ma	nce

Yes

Check completeness

Yes

Check stability

Yes

Check logical consistency

Yes

Data characterisation

Data characterisation conducted

Yes

Data characterisation moment

after data extraction
after extract-transform-load to a common data model
after creation of study variables